Skip To Content
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Before it's here, it's on the Bloomberg Terminal.
Learn More
AUTL:USNASDAQ GS

Autolus Therapeutics PLC

COMPANY INFO
15.41USD
-0.65-4.05%
Market Closed
As of 06/14/2019 EDT
Open
16.00
Prev Close
16.06
Volume
80,915
Market Cap
693.074M
Day Range
15.4116.21
52 Week Range
15.0753.24
1D1M1Y5Y
View Full Chart
Market Closed
As of 06/14/2019 EDT
1D1M1Y5Y
View Full Chart
markets
A Conversation With People’s Bank of China Governor Yi Gang
Before it's here, it's on the Bloomberg Terminal.
Learn More
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Key Statistics

P/E Ratio--
Bloomberg (BEst) P/E Ratio--
Bloomberg (BEst) PEG Ratio--
Shares Outstanding44.98M
Price to Book Ratio2.8395
Price to Sales Ratio--
1 Year Return--
30 Day Avg Volume106,600
EPS--
Bloomberg (BEst) EPS Curr Yr-1.5570
Dividend--
Last Dividend Reported--
Earnings Announcement for Period Ending Q1/2019:08/15/2019

Compare
1-Day Performance

-5%0
-5%0
Equity
AUTL:US
-4.05%
Sponsored By

About Autolus Therapeutics PLC

Autolus Therapeutics plc operates as a bio-pharmaceutical company. The Company develops cell therapies for the treatment of cancer. Autolus Therapeutics serves clients in the United Kingdom.
Address
Forest House 58 Wood Lane, White City London, W12 7RZ United Kingdom
Phone
44-20-3829-6230
Website
www.autolus.com

Income Statement

Quarterly
Annual
;
Q1 2019 (Millions USD)
  • Revenue
    1.96
  • Net Income
    -27.18
  • Profit Margin
    -1,383.86%

Balance Sheet

Quarterly
Annual
;
Q1 2019 (Millions USD)
  • Total Assets
    264.36
  • Total Liabilities
    46.47
  • Debt to Assets
    10.65%

Cash Flow

Quarterly
Annual
Q1 2019 (Millions USD)
  • Operating
    -26.52
  • Investing
    -7.33
  • Financing
    4.71